NPR's Michel Martin speaks to Star Tribune reporter Andy Mannix about the investigation into the Minneapolis police and EMTs sedating people in custody.
Many people at high risk for HIV can't afford PrEP, though it's more than 90 percent effective if taken daily. Its list price, close to $2,000 for a 30-day supply, has risen 45 percent in six years.
McMath was put on life support in 2013 after a tonsillectomy. Doctors said she had irreversible brain damage, and a coroner issued a death certificate. Her mother never agreed with that assessment.
After surgery for separate hand injuries, a father and son endured lengthy occupational therapy, which their insurer considered to be an alternative treatment. The family owed more than $8,500.
ProPublica found that drugmakers spent less to market opioids to doctors in 2016 than in prior years. Studies have shown that payments to doctors are linked to more prescriptions for the drugs.
A Harvard Medical School project aims to become the first national registry for exceedingly rare cancer patients who respond mysteriously well to treatments that failed to help others.
The doctor and health care critic hopes to design a better system for more than 1 million workers at Amazon, Berkshire Hathaway and JPMorgan Chase. Data-driven solutions can improve outcomes, he says.
Duke University researchers say some patients with brain cancer survived long after receiving treatment with a weakened poliovirus. But the response rate was limited and there were side effects.
For the first time, the FDA has approved a drug containing CBD, an extract of marijuana. This move could pave the way for more research into medical uses for the marijuana extract.
The company released a statement defending its pharmacist's right to decline to fill a prescription on ethical grounds. The state pharmacy board plans to investigate whether Arizona law was followed.